论文部分内容阅读
目的 通过与传统经典方案CAP的疗效、毒性的比较 ,探讨去甲长春花碱和顺铂 (NP方案 )联合用于非小细胞肺癌 (NSCLC)的新辅助化疗 (NCRT)的可行性。方法 对 30例II期 ,IIIa期NSCLC患者以去NP方案手术前化疗 2个疗程 ,对照组 42例以CAP方案化疗 2个疗程 ,按WHO标准评价临床疗效 ,按WHOO IV度标准评价毒性反应。结果 (1)实验组化疗总缓解率 (RR)为 40 .0 % ,其中CR1例 ,PR 11例 ,对照组RR为 2 8.5 7% ,其中CR0例 ,PR12例。 (2 )NCRT中出现一定程度毒性作用 ,以粒细胞降低为主 ,实验组与对照组虽有差别 ,但无统计学意义。患者恢复迅速 ,全组病例在第二疗程后 3周内手术 ,全部病例能耐受手术 ,未出现围手术期内死亡。结论 去甲长春花碱和顺铂能有效、安全用于NSCLC的NCRT中
Objective To investigate the feasibility of neoadjuvant chemotherapy (NCRT) combined with vinblastine and cisplatin (NP regimen) for non-small cell lung cancer (NSCLC) by comparing the efficacy and toxicity of traditional classic CAP. Methods Thirty patients with stage IIa, stage IIIa NSCLC were treated with NP regimen for 2 courses of chemotherapy, 42 patients in the control group were treated with CAP regimen for 2 cycles. Clinical efficacy was evaluated according to the WHO criteria. The toxicity was evaluated according to WHOO IV criteria. Results (1) The total remission rate (RR) of the experimental group was 40.0%, of which CR1 cases, PR 11 cases, control group RR was 28.57%, CR0 cases, PR12 cases. (2) There was a certain degree of toxic effect in NCRT, mainly in granulocyte reduction, although there was a difference between the experimental group and the control group, but there was no statistical significance. The patient recovered rapidly. All the cases were operated within 3 weeks after the second course of treatment. All cases were able to tolerate the operation and no perioperative death occurred. Conclusion Navelbine and cisplatin can effectively and safely be used in NCRT of NSCLC